Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lee Schwartzberg

Showing results (21-30 of 112) with videos related to

Pageof 12
Sort By:
Critical Reviews in Oncology/Hematology|December 1, 2020
Efficacy of intravenous NEPA, a fixed NK<sub>1</sub>/5-HT<sub>3</sub> receptor antagonist combination, for the prevention of chemotherapy-induced nausea and vomiting (CINV) during cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy: A review of phase 3 studiesMatti Aapro, Rudolph M Navari, Eric Roeland, et al.
Future Oncology (London, England)|March 13, 2019
Preventing chemotherapy-induced nausea and vomiting with netupitant/palonosetron, the first fixed combination antiemetic: current and future perspectiveMatti Aapro, Li Zhang, Sriram Yennu, et al.
American Health & Drug Benefits|September 18, 2015
Resource Utilization for Chemotherapy-Induced Nausea and Vomiting Events in Patients with Solid Tumors Treated with Antiemetic RegimensLee Schwartzberg, Brooke Harrow, Lincy S Lal, et al.
Journal of Medical Economics|July 20, 2013
Indirect costs associated with metastatic breast cancerYin Wan, Xin Gao, Sonam Mehta, et al.
Clinical Therapeutics|December 25, 2003
A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemiaLee Schwartzberg, Roger Shiffman, Dianne Tomita, et al.
Current Medical Research and Opinion|June 24, 2011
Chemotherapy-induced nausea and vomiting and antiemetic prophylaxis with palonosetron versus other 5-HT3 receptor antagonists in patients with cancer treated with low emetogenic chemotherapy in a hospital outpatient setting in the United StatesLee Schwartzberg, Gary Morrow, Sanjeev Balu, et al.
The Oncologist|December 15, 2025
Safety and efficacy of same-day administration of eflapegrastim in patients with early-stage breast cancer receiving chemotherapyManuel Modiano, Shanta Chawla, Jeffrey L Vacirca, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 30, 2009
Cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small cell lung cancerRobert Klein, Catherine Muehlenbein, Astra M Liepa, et al.
Biomed Research International|October 1, 2015
A Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and VomitingPaul J Hesketh, Matti Aapro, Karin Jordan, et al.
European Journal of Cancer (Oxford, England : 1990)|February 7, 2016
Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapyBernardo Rapoport, Lee Schwartzberg, Martin Chasen, et al.
Pageof 12

Showing results (21-30 of 112) with videos related to

Sort By:
Pageof 12
Critical Reviews in Oncology/Hematology|December 1, 2020
Efficacy of intravenous NEPA, a fixed NK<sub>1</sub>/5-HT<sub>3</sub> receptor antagonist combination, for the prevention of chemotherapy-induced nausea and vomiting (CINV) during cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy: A review of phase 3 studiesMatti Aapro, Rudolph M Navari, Eric Roeland, et al.
Future Oncology (London, England)|March 13, 2019
Preventing chemotherapy-induced nausea and vomiting with netupitant/palonosetron, the first fixed combination antiemetic: current and future perspectiveMatti Aapro, Li Zhang, Sriram Yennu, et al.
American Health & Drug Benefits|September 18, 2015
Resource Utilization for Chemotherapy-Induced Nausea and Vomiting Events in Patients with Solid Tumors Treated with Antiemetic RegimensLee Schwartzberg, Brooke Harrow, Lincy S Lal, et al.
Journal of Medical Economics|July 20, 2013
Indirect costs associated with metastatic breast cancerYin Wan, Xin Gao, Sonam Mehta, et al.
Clinical Therapeutics|December 25, 2003
A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemiaLee Schwartzberg, Roger Shiffman, Dianne Tomita, et al.
Current Medical Research and Opinion|June 24, 2011
Chemotherapy-induced nausea and vomiting and antiemetic prophylaxis with palonosetron versus other 5-HT3 receptor antagonists in patients with cancer treated with low emetogenic chemotherapy in a hospital outpatient setting in the United StatesLee Schwartzberg, Gary Morrow, Sanjeev Balu, et al.
The Oncologist|December 15, 2025
Safety and efficacy of same-day administration of eflapegrastim in patients with early-stage breast cancer receiving chemotherapyManuel Modiano, Shanta Chawla, Jeffrey L Vacirca, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 30, 2009
Cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small cell lung cancerRobert Klein, Catherine Muehlenbein, Astra M Liepa, et al.
Biomed Research International|October 1, 2015
A Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and VomitingPaul J Hesketh, Matti Aapro, Karin Jordan, et al.
European Journal of Cancer (Oxford, England : 1990)|February 7, 2016
Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapyBernardo Rapoport, Lee Schwartzberg, Martin Chasen, et al.
Pageof 12